Canadian clinical practice guidelines published in CMAJ for the management of opioid use disorders recommend clinicians use buprenorphine–naloxone as first-line opioid agonist treatment when possible, utilize a stepped and integrated care approach and reject withdrawal management alone.

“Opioid use disorder is a public health emergency nationwide, and this guideline provides a blueprint for health practitioners to step up and provide evidence-based care,” Julie Bruneau, MD, Centre hospitalier de l’Université de Montréal, said in a press release.

Read more at:

https://www.healio.com/psychiatry/substance-use-disorders/news/online/%7B43ec8c00-ab0e-4e8a-a69e-5671a013dfd4%7D/canadian-guidelines-urge-buprenorphine-naloxone-to-treat-opioid-use-disorders
Healio Psychiatry
March 5, 2018

Canadian guidelines urge buprenorphine-naloxone to treat opioid use disorders – 2018-03